143 Avsnitt

  1. Complete response to talazoparib in patient with pancreatic adenocarcinoma harboring somatic PALB2 mutation: A case report and literature review

    Publicerades: 2023-02-02

  2. Basics of prostate cancer pathology

    Publicerades: 2023-01-26

  3. Oligometastaic breast cancer

    Publicerades: 2023-01-19

  4. Artificial intelligence for prediction of treatment outcomes in breast cancer: Systematic review of design, reporting standards, and bias

    Publicerades: 2023-01-12

  5. Summary/Review - Reporting Guidelines - CHEERS

    Publicerades: 2022-12-06

  6. Role of immunotherapy in head and neck cancer

    Publicerades: 2022-12-01

  7. AYAs with cancer: the right to be forgotten

    Publicerades: 2022-11-24

  8. Summary/Review - Reporting Guidelines - SQUIRE

    Publicerades: 2022-11-17

  9. Male breast cancer

    Publicerades: 2022-11-10

  10. Summary/Review - Reporting Guidelines - SRQR

    Publicerades: 2022-11-03

  11. Summary/Review - Reporting Guidelines - AGREE

    Publicerades: 2022-10-27

  12. Breast Cancer: Frequently Asked Questions and Answers

    Publicerades: 2022-10-20

  13. The role of Medical Physicist in Oncology

    Publicerades: 2022-10-13

  14. How to approach to breast cancer patient who had not received neoadjuvant chemo and staged T2NO postoperatively?

    Publicerades: 2022-10-06

  15. Parp inhibitors in ovarian cancer

    Publicerades: 2022-09-29

  16. Primary endocrine resistant in recurrent locoregional only Breast cancer (role of endocrine therapy)

    Publicerades: 2022-09-22

  17. Should Prostate Cancer Patients With History of Cardiovascular Events Be Preferentially Treated With Luteinizing Hormone-Releasing Hormone Antagonists?

    Publicerades: 2022-09-15

  18. The use of Lutetium PSMA as treatment in mCRPC – in what sequence and how to best select patients

    Publicerades: 2022-09-08

  19. Use of Medical Cannabis in Oncology. Knowledges and attitudes among oncologist and patient.

    Publicerades: 2022-09-01

  20. Tissue-agnostic drug approvals: how does this apply to patients with breast cancer?

    Publicerades: 2022-07-27

4 / 8

e-ESO is the online platform of the European School of Oncology providing sponsor-free, open access quality education wherever you are in the world. www.e-Eso.net

Visit the podcast's native language site